To ensure all arms in a randomized clinical trial have roughly equal percentages of participants from key subgroups, statisticians often stratify patient assignment to each arm and account for these ...
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung This trial had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback